SBIR Phase I: Faecalibacterium prausnitzii supernatant oral formulations to improve insulin sensitivity and treat prediabetes

SBIR 第一阶段：普拉梭菌上清液口服制剂，可提高胰岛素敏感性并治疗糖尿病前期

• 批准号: 2151168
• 负责人: Simon McManus
• 金额: $ 25.6万
• 依托单位: BACTANA CORP.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2023-10-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2151168&HistoricalAwards=false
• 关键词: SBIR; Phase; Faecalibacterium; prausnitzii; supernatant

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to prevent and treat prediabetes and type 2 diabetes. More than 1 in 3 American adults have prediabetes or type 2 diabetes with associated healthcare costs exceeding $327 billion. Current therapies often present adverse effects or are ineffective in some patients. The top five human diabetes drugs alone are expected to cost $23 billion annually by 2024. This project advances a novel diabetic treatment composed of a postbiotic mixture from beneficial gut bacteria. This will improve clinical outcomes for prediabetic patients.This Small Business Innovation Research (SBIR) Phase I project will evaluate the efficacy and elucidate the mechanism of a potential microbiome-based treatment toward an oral treatment that effectively reduces diabetes-associated markers. The three technical objectives are to: 1) evaluate the technology and demonstrate equivalent or superior performance compared to existing antidiabetic drugs, 2) better understand the mechanism that leads to efficacy in the treatment of prediabetes and type 2 diabetes, and 3) identify the active molecule(s) from the postbiotic mixture. These objectives will be carried out using rodent trials, cell-based assays, and advanced separation techniques.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业创新研究 (SBIR) 第一阶段项目更广泛的影响/商业潜力是预防和治疗糖尿病前期和 2 型糖尿病。超过三分之一的美国成年人患有糖尿病前期或 2 型糖尿病，相关医疗费用超过 3,270 亿美元。目前的疗法常常对某些患者产生副作用或无效。到 2024 年，仅前五种人类糖尿病药物预计每年花费 230 亿美元。该项目提出了一种由有益肠道细菌的后生元混合物组成的新型糖尿病治疗方法。这将改善糖尿病前期患者的临床结果。这个小型企业创新研究 (SBIR) 一期项目将评估功效并阐明潜在的基于微生物组的治疗的机制，以有效减少糖尿病相关标志物的口服治疗。这三个技术目标是：1) 评估该技术并证明与现有抗糖尿病药物相比具有同等或优越的性能，2) 更好地了解治疗前驱糖尿病和 2 型糖尿病的疗效机制，以及 3) 确定活性药物来自后生元混合物的分子。这些目标将通过啮齿动物试验、基于细胞的分析和先进的分离技术来实现。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力优点和更广泛的影响审查标准进行评估，被认为值得支持。